Understanding the mechanisms leading to progressive immunodeficiency and identifying correlates of such immunodeficiency and its reversal are critical to improving management of human immunodeficiency virus (HIV) infection and to developing innovative new treatment strategies. CD4 + cell counts and plasma HIV RNA levels have been validated as surrogate markers for HIV disease progression and response to therapy [1, 2] . However, other putative markers, which may be valid surrogates for immune recognition (i.e., demonstrating correlation with immunizing events, such as tetanus vaccination) have not been validated as surrogate measures for HIV disease progression (i.e., the occurrence of AIDS-defining events or death) in prospective studies. These include in vivo and in vitro functional measures of immune recognition, such as lymphocyte proliferation assays, delayed-type hypersensitivity reaction, antibody formation, and cytokine production assays. Do these parameters supply clinically useful information beyond that provided by the CD4 + cell count? Should these assays be used in management of HIV disease or as end points in clinical studies of therapeutic interventions?
In this issue of The Journal of Infectious Diseases, Lederman et al. [3] sought to determine which of a number of immunologic markers commonly used in HIV research could reliably identify patients at risk for developing opportunistic complications by studying a cohort of patients with nadir CD4 + cell counts of !50 cells/ mm 3 . It is the largest such study to date. They made 2 important observations: first, that, regardless of the immunologic parameter examined, a substantial proportion of patients had laboratory evidence of impaired immunologic function, and second, that, regardless of the results of the immunologic studies, the incidence of opportunistic complications was extremely low. Thus, the immunologic markers studied failed to predict clinical outcome following antiretroviral treatment. These findings raise some disturbing questions about the meaning, relevance, and use of these immunologic surrogates in management of HIV disease.
The study analyzed data from a trial that was initially developed to determine the safety of discontinuing Mycobacterium avium complex primary prophylaxis after antiretroviral treatment for late-stage HIV disease [4] . Recognizing the unique opportunity available to them, the investigators chose to continue the study to better characterize immune reconstitution in this cohort of patients who had severe immunodeficiency before initiation of effective antiretroviral therapy. Analyzing 643 patients followed up for nearly 3 years in the main cohort, including 199 patients included in a more intensively studied subcohort, the authors compared surrogate measures for immune function against the likelihood of developing an AIDS-defining illness. None of the surrogate measures, which included lymphocyte proliferation assays, delayed-type hypersensitivity reaction, and antibody formation, correlated with clinical events. In addition, the authors also measured lymphocyte subsets, including phenotypic naive (CD45RA [5] [6] [7] . Surprisingly, there was a poor correlation among positive responses to the same antigen, tetanus toxoid (as measured by lymphocyte proliferation assay or delayed-type hypersensitivity skin test), in the same patient, which further high-lights the difficulties in interpreting the results of these assays. Even when these assays were compared with accepted surrogates of disease progression, total CD4 + cell number and HIV RNA levels, there was relatively poor correlation with the studied surrogates. Thus, this study finds no support for the use of these immune assays as surrogates for HIV disease progression.
However, this conclusion must be tempered by the deficiencies of the study. Most importantly, the study was underpowered, because the therapy used was more effective than anticipated, as a result of which far fewer patients progressed to AIDS-defining illnesses than had been predicted in the study design. In addition, because patients were enrolled only after their CD4 + cell counts had increased to 1100 cells/mm 3 (the median baseline CD4 + cell count was 226 cells/mm 3 ), the study selected for patients who had already demonstrated a substantial level of immune reconstitution and excluded patients with a potentially greater level of immunodeficiency and higher risk of progression of disease. Furthermore, given that clinical evidence of immune reconstitution can be seen soon after the initiation of effective antiretroviral therapy, changes in immunologic surrogates might have correlated with clinical outcome, had pretreatment or early posttreatment measurements been available. The results may also have been confounded by the fact that one-third of patients had measurable plasma HIV RNA levels. Unfortunately, it is unlikely that studies addressing these concerns will be conducted in the foreseeable future, given the difficulties in studying large cohorts of patients with data from pretreatment time points over long periods of time in countries where antiretroviral therapy is widely used.
Nonetheless, the weight of existing published evidence supports the discordance between the clinical improvements so familiar to physicians who specialize in HIV and the impaired responses in putative surrogate markers of immune function other than CD4 + cell counts [8] [9] [10] [11] . There are at least 2 possible interpretations for this poor correlation. First, the surrogate markers studied may be sensitive measures of an aspect of immune function, but, in the setting of HIV infection and antiretroviral treatment, they may measure subtle abnormalities that do not correlate with an increased risk of developing an AIDSdefining illness. However, such abnormalities would reflect, for example, susceptibility to hepatitis A virus infection in the 56% of study participants who did not develop a serologic response to vaccination. The second possibility is that the immunologic markers studied are insensitive and do not appropriately reflect immune reconstitution. Under this second interpretation, again using the example of hepatitis A vaccination, patients would be protected against infection, even though they have negative results of tests of a surrogate measure of immunity. Although the study may have been underpowered to detect correlations between abnormalities in specific assays and opportunistic complications, it is remarkable that, during the nearly 3 years of followup, widespread and sustained impairment was seen in these assays and so few clinical events occurred. What meaning do deficiencies detected by surrogate markers of immune recognition have in the setting of HIV disease-are they believable, are they real or relevant, what do the assays actually measure, what, in fact, are they surrogates for? Are immunologic deficiencies the result of an ongoing process induced by persistent but controlled HIV infection, or residua from damage that occurred before the initiation of antiretroviral therapy? Are patients with late-stage HIV infection susceptible to diseases such as hepatitis A, despite remote or recent vaccination? Should patients with late-stage infection defer preventative vaccines until they are receiving antiretroviral therapy, and, if so, for how long? These myriad questions are unsettling, and many can only be answered in clinical end-point trials. However, given the clinical success of antiretroviral therapy, it seems unlikely that such trials would be judged either necessary or cost-effective. This suggests that more creative approaches are needed. For example, it would be possible, in the context of a large-scale vaccine efficacy trial, to validate both the efficacy of a vaccine and the surrogate measure of immune exposure to that vaccine.
Intensive immunologic studies focusing on a small number of patients will continue to provide important clues to potential pathogenic mechanisms of HIV disease. However, despite the barriers to validating these observations in large-scale clinical end-point trials, such validation is critical to identifying relevant surrogates. Until surrogate markers have been validated, conclusions of benefit ascribed to therapeutic interventions based on improvements in such markers are unwarranted. Moreover, it is time to move beyond the immune assays studied by Lederman et al. [3] , because these assays have not been shown to have any meaningful relationship with future clinical outcome. For the present, clinicians must continue to rely on CD4 + cell counts, plasma HIV RNA levels, and clinical clues of immunodeficiency, such as persistent fever or unexplained oropharyngeal candidiasis, to guide antiretroviral therapy and opportunistic infection prophylaxis.
